Next Article in Journal
A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC)
Next Article in Special Issue
Multiple Myeloma in 2023 Ways: From Trials to Real Life
Previous Article in Journal
The Confusion Assessment Method Could Be More Accurate than the Memorial Delirium Assessment Scale for Diagnosing Delirium in Older Cancer Patients: An Exploratory Study
Previous Article in Special Issue
Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 30
Issue 9
10.3390/curroncol30090599
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature

by
Giuseppe Maggioni
1,*,
Marny Fedrigo
2,
Andrea Visentin
3,*,
Elisa Carturan
2,
Valeria Ruocco
3,
Livio Trentin
3,
Mauro Alaibac
4 and
Annalisa Angelini
2
1
Pathology Unit, Department of Medicine, University of Padova, Via A. Gabelli 61, 35121 Padova, Italy
2
Cardiovascular Pathology Unit, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy
3
Hematology Unit, Department of Medicine, University of Padova, Via N. Giustiniani 2, 35128 Padova, Italy
4
Dermatology Unit, Department of Medicine, University of Padova, 35128 Padova, Italy
*
Authors to whom correspondence should be addressed.
Curr. Oncol. 2023, 30(9), 8255-8265; https://doi.org/10.3390/curroncol30090599
Submission received: 26 July 2023 / Revised: 4 September 2023 / Accepted: 5 September 2023 / Published: 7 September 2023
(This article belongs to the Special Issue Haematological Neoplasms: Diagnosis and Management)
Browse Figures
Review Reports Versions Notes

Abstract

:
Severe mucormycosis is a fatal disease rarely complicating chronic lymphoproliferative disorders. We present a fulminant and fatal case of a 74-year-old Caucasian woman suffering from CLL treated with second-generation BTK inhibitor zanubrutinib. After a first septic episode a month prior, originating from the lung with later systemic involvement by an unidentified agent and treated with large-spectrum antibiotics and fluconazonle, a slow-onset enlarging tender warm and erythematous nodular swollen cutaneous lesion appeared in her lower limbs and spread subsequently to her upper limbs, progressing towards central ulceration with a necrotic core. Suspecting a mycotic dissemination from an unknown agent, a skin punch biopsy was performed, and intraconazole was started. Due to spread of the skin lesions, the patient was hospitalized and intravenous liposomal ampthotericin B was started. Histopathology showed an atypical sporangium-rich mycotic angioinvasion of the small vessels. Only the increase of BDG and GM could corroborate the hypothesis of mycotic infection. However, long-term CLL, immunosuppressive therapies, neutropenia, and prior use of azoles and other antimycotic agents were risk factors for mucormycosis; BTK inhibitor could also be added as another novel risk factor. Despite all therapeutic efforts, the patient died. Post-mortem molecular exams confirmed the diagnosis of disseminated mucormycosis.

1. Introduction

Chronic lymphocytic leukaemia (CLL) is a haematological malignancy characterized by the clonal proliferation of long-lived CD5+ B lymphocytes in spleen and lymph nodes, bone marrow, and peripheral blood [1]. It is often associated with immune system dysregulation [2], which represents a contributing factor in the overall clinical picture.
The immune system dysregulation could be at least partly explained by CLL cells expressing high levels of the immune-suppressing cytokines, including TGF-β and IL-10 [3], low levels of adhesion and costimulatory molecules essential for the induction of effective immune responses, and an increased numbers of regulatory T-lymphocytes [4]. Other relevant elements are the alteration of both node and bone marrow microenvironments, creating a niche favouring the survival of neoplastic cells and impinging the immune responses caused by T-lymphocytes [5]. In addition, T-lymphocytes display markers of immune exhaustion, such as PD-1 (programmed cell death protein (1), that hinder their activation and function against the neoplastic cells [6]. Hypogammaglobulinemia is another common clinical characteristic of the CLL immune dysregulation. It can be found in almost 25% of the patients at diagnosis and up to 85% of relapsed and heavily treated cases [7]. It is usually a non-reversible phenomenon that increases the risk of infection. Infections are still the main cause of death among patients with CLL, accounting for 25–50% of the mortality rate in these patients [8,9]. The abovementioned immune dysregulation is further worsened by medical treatments, such as not chemoimmunotherapy, but also Bruton’s tyrosine kinase (BTK) inhibitors. This novel class of drugs revolutionized the treatment landscape for patients with CLL. BTK is a cytoplasmic tyrosine kinase that is important in B-lymphocyte development, survival, activation, and differentiation [10], and its dysregulation is a CLL pathogenic hallmark [1]. These drugs are meant to disrupt the aberrant activation of the B-cell receptor (BCR), leading to cell death [11]. However, these inhibitors can also modulate the immune microenvironment, shaping the activity of several immune cells, impacting an already-altered immune system, and raising concerns about their potential effects on susceptibility to infections, including mycetes. BTK inhibitors may impair innate immunity [12] and adaptive immunity and more specifically, BTK inhibition may impair T-lymphocyte function, shifting to a marked Th-1 selection with lower antibody production, and lower immune surveillance against pathogens [13]. Moreover, BTK also has a pivotal role in other immune cell populations, including macrophages, where it regulates receptor-mediated phagocytosis, including the phagocytosis of fungal organisms such as Candida albicans [14]. However, the infectious risks associated with BTK pharmacologic blockade remain poorly defined, despite reports of opportunistic infections in patients who received ibrutinib treatment, including cases of Pneumocystis jirovecii pneumonia (PJP), cryptococcosis, and invasive mould infection (including Mucorales), are becoming progressively more common [15]. BTK inhibitors could be therefore potentially considered a risk factor of infectious complications in CLL patients [12,16,17,18,19].
Given the previous points and the wide clinical use of BTK inhibitors, physicians should be aware of the risk to develop severe invasive mycosis.
Apart from the more common and well-documented infections by Candida and Aspergillus spp., mycetes belonging to the order of Mucorales represent a major clinical issue in CLL. Fungi belonging to this recently re-classified order [20,21,22,23] account for 38 species (out of 261 total) in 55 genera that have been reported to be responsible for clinically relevant pathologies in human patients [23,24]. The most prevalent genus causing clinical mucormycosis is Rhizopus (two main species) [25], followed by the genus Mucor (twelve species up to date) [24], Lichtheimia, and Rhizomucor; other less frequent pathogenic species are occasionally reported [26,27]. The fast growth, airborne spores, and the thermotolerance of these ubiquitarian saprotroph moulds enable them to grow at human body temperature: these features explain their pathogenic activity in patients with specific risk factors, including SARS-CoV-2 infection and treatments [28,29], as listed in Table 1 [20,26,30].
Little is known so far about these fungal cell structures, especially regarding the components of their cell wall [36] as well as their biology and metabolism, and this has a major clinically negative impact, both on the diagnostic side (laboratory tests on serum or other human fluids) and on the therapeutic side (the correct administration of specific drugs). Two main serological assays are used to detect mycosis: (1-3)-β-D-glucan (BDG) and galactomannan (GM). Both of these target key polysaccharide components of the fungal cell wall. These tests are particularly useful in a couple of specific situations: neutropenic fever due to hematologic malignancy and patients receiving transplants [37,38,39,40]. However, as stated in an important retrospective paper by Millon et al., GM and BDG tests display a low sensibility during mucormycosis, and tissue cultures take several days and are often negative, preventing early management [41]. The epidemiology of mucormycosis is complex to estimate, but it seems underrated even though there are studies showing growth, probably due to the increasing number of immunocompromised patients [42].
The clinical landscape of mucormycosis is heterogeneous. The infection is classified based on the anatomical site: rhino-orbito-cerebral (ROCM), pulmonary, gastrointestinal [43], cutaneous, and other miscellaneous [25,31,44]. They are also stratified according to the underlying risk factor [45].
Cutaneous mucormycosis can be seen not only in immunocompromised hosts, but also in immunocompetent patients [35,46,47]. The most common aetiology, regardless of the risk factors, is penetrating trauma, followed by iatrogenic lesions, including intramuscular injections and open wound trauma.
Based on the extent of invasion, cutaneous mucormycosis can be classified as a localized infection, deep extension, or a specific localization of a disseminated infection. A localized infection is seen in 32–56% of patients, usually restricted to the cutaneous and subcutaneous tissue without invading adjacent sites. Deep extension refers to the invasion of muscles, bones, and tendons, occurring in 24–52% of patients. In these cases, the infection often presents as necrotizing fasciitis with erythematous necrotic eschar. Cutaneous mucormycosis as part of a disseminated infection and refers to an infection involving other non-contiguous sites besides the cutaneous site, and is seen in 16–20% of cutaneous infections [44]. These infections are extremely burdensome for the healthcare system, leading to prolonged hospitalization and increased healthcare costs [48,49].
Here, we present the case of a fulminant fatal cutaneous mould infection in a 74-year-old Caucasian female patient suffering from chronic lymphocytic leukaemia (CLL).

2. Detailed Case Description

A 74-year-old female patient, a retired employee, was admitted to the haematology ward on 4 July 2020 after a progressive decline in her clinical condition. The patient lived alone and denied any foreign travel, skin trauma, abrasions, or the possession of pets. Apart from a less significant femoral head necrosis with an arthroprosthesis, her medical history was positive for CLL since 2006, characterized by a complex karyotype, TP53 mutation, and trisomy 12 at FISH [50,51]. She had undergone several lines of therapy, as listed in Table 2. She also had hypogammaglobulinemia, for which she was receiving subcutaneous immunoglobulins, but no diabetes mellitus.
Her medical history was complicated by several hospitalizations due to infections, including H1N1 influenza in 2016, primarily related to her immunosuppressive state and bronchiectasis.
Approximately one month prior (towards the end of May 2022), the patient was admitted to hospital due to pulmonary sepsis caused by an unidentified agent. The condition was managed with ceftriaxone, levofloxacin, and fluconazole. After an infectious disease consultation, the treatment was switched to meropenem, daptomycin, and caspofungin, leading to complete resolution.
Immediately after the discharge (4 June) blood tests showed a marked and gradual increase in C-reactive protein (CRP) levels along with concomitant grade 4 neutropenia (i.e., <500/μL) lasting for more than 15 days. The patient also experienced a subsequent febrile peak. Starting from mid-June (referring to the period from 15 June on), tender, warm, erythematous nodular swollen cutaneous lesion appeared in the lower limbs and subsequently also spread to the upper limbs. These lesions exhibited central ulceration with a necrotic core as they progressed (Figure 1).
In suspicion of a fungal infection, a lesion biopsy was performed on 25 June. Zanubrutinib was discontinued, and empirical therapy with oral itraconazole was initiated immediately after the biopsy.
A 5 mm Ø punch biopsy of the cutis and subcutis was conducted on the left thigh at the interface of the necrotic core and the macroscopically intact cutis. The biopsy specimen was fixed in a 10% neutral formalin solution. Macroscopic examination revealed dark skin pigmentation along with a 1 mm brownish nodular lesion without any other relevant features.
In total, four stains were applied in addition to standard HE staining: Giemsa, GMS (Grocott–Gömöri methenamine silver stain), PAS (Periodic acid–Schiff), and Gram staining. Photographic documentation of the resulting slides was captured at various magnifications (see Figure 2 and Figure 3).
Microscopic analysis highlighted a severe, diffuse lympho-monocytic inflammation. Minimal to no necrotic material was observed. Sparse microbial structures exhibited a typical angioinvasive pattern, including thrombosed arterioles and small blood vessels. Hyphal mats and sporangial-type cells (specialized cells forming spores) were identified. Inside the vessels, a minute pauciseptate (coenocytic), thin-walled (5–15 µm), and minimally branching (at most) hyphal mat formed the primary histopathological finding. Additionally, numerous thick-walled ovoidal or spheroidal (5–20 µm) sporangia were detected within the relatively scarce vegetative hyphae. These thick-walled structures strongly stained with PAS, GMS, and Giemsa. Slide examination immediately disclosed many critical points, due to the aggressive presentation of a rare cutaneous infection from an unknown site.
The case was extensively discussed, and specialized Veterinary Pathologists from our University were consulted. Given the complexity of the case and the lack of positive laboratory evidence, only a presumptive diagnosis of deep cutaneous fungal infection was reached. The anatomopathological report listed rhinococcidioidomycosis, chromoblastomycosis, or scytalidosis as potential diagnostic alternatives.
In suspect of severe mould infection, clinical findings and X-ray study of the chest were conducted, but they excluded local recurrences of infection. Furthermore, sinonasal clinical findings were negative. Itraconazole treatment proved ineffective, and cutaneous nodules increased after 10 days of therapy. The patient was hospitalized and was managed with liposomal amphotericin B (L-AmB) 10 mg/kg daily. Although this approach slowed down the progression of cutaneous lesions, a consistent increase in BDG and GM was observed from the first day, suggesting a potential co-infective progression to, likely, mycotic bronchopneumonia. In such a disseminated form of disease, the mortality rate is exceedingly high [52].
Unfortunately, both pathogen culture from the cutaneous scratch and multiple-site repeated blood cultures yielded no positive results. While Mucorales species are known as angioinvasive fungi, positive blood culture results are infrequent unless there is luminal involvement of a vascular catheter [53].
Ultimately, despite all therapeutic interventions attempted, the patient passed away after 30 days of hospitalization. No autopsy was required by physicians.

3. Discussion

Invasive fungal infections are rare in patients with lymphoproliferative disease like CLL [54,55], although they are associated with a dismal prognosis [56]. While BTK inhibitors have improved the treatment landscape for CLL patients, they have been linked to adverse events, such as atrial fibrillation, bleeding, diarrhoea, and infections [57,58]. Despite their selectivity towards BTK, these inhibitors can also impact other kinases, such as ITK, EGFR, and TEC, leading to adverse effects. BTK inhibitors like ibrutinib and zanubrutinib have been reported to impair the innate response against fungal infections by affecting BTK in macrophages [59].
Following the patient’s demise, the case was completely re-examined histologically and subsequently discussed collectively, taking into account the entire clinical history. Molecular analysis through DNA extraction became the final step in establishing the definitive, accurate diagnosis of an invasive fungal infection (IFI) caused by invasive mucormycosis.
There are a few issues related to this case which should be addressed.
The clinical diagnosis of fungal infection in this case was challenging. First of all, the distinctive type of infection prompted the consideration of parasitic diseases, including rare ones. The exclusion of both unicellular and multicellular parasites was guided by two main indicators: the pronounced positivity of cell walls with GMS staining and serological positivity for fungal markers.
Despite its relative weakness, GM positivity in laboratory tests (a week after the biopsy) brought invasive aspergillosis into the differential diagnosis, given also the recent pneumonia. The mould appearance of aspergillosis is often mistaken for mucormycosis. The size of hyphae is usually an element of distinction, whereas hydropic and swollen aspergillar hyphae cannot be clearly distinguished from Mucorales hyphae. No primary focus of infection was identified; this complicated the identification of the pathogen, giving rise to doubts in the differential diagnosis. The histological elements were non-conclusive as well. Severe angioinvasive pattern is a pivotal element in disseminated mycosis. In disseminated aspergillosis, it is not uncommon to see hyphae invading dermal blood vessels walls, producing septic emboli and causing thrombosis and associated necrosis [60]. In retrospect, the branching at right angles and rare septation, as partially seen in our slides (Figure 3), could have possibly been considered a hint. Another critical histological element that misled the diagnosis towards coccidiodomycosis was the presence of numerous large sporangia. Nevertheless, this element was in contrast with the medical history of the patient, i.e., denying visiting foreign countries.
Serological fungal markers themselves provide little help in mucormycosis diagnosis [41], similarly to blood and tissue cultures. In fact, despite Mucorales species being highly angioinvasive fungi, even with the demonstration of positive histopathologic hyphae, blood cultures that allow for proper antibiograms only turn positive in about 50% of cases [53,61], as was in our case. New and promising techniques have been under development, including an ELISA test reacting for highly purified fucomannan wall carbohydrates of Mucor spp. [61,62].
Isolating the pathogen in a case with an uncertain diagnosis is essential for several reasons. This includes identifying potential sources of contamination within sensitive wards that house vulnerable patients and enhancing overall patient management. Moreover, recent studies highlight unpredictable antifungal susceptibility within the same Mucorales order [24], leading to unforeseeable drug combinations, like L-AmB and caspofungin. (This last one usually seen as ineffective based on clinical and laboratory experience due to its high minimal inhibiting concentration (MIC) [63,64]). Surprisingly, this combination has shown effectiveness not only in murine models [65], but also in promising case reports [66,67], even from highly endemic areas [28], despite being limited to ROCM and diabetic ketoacidosis patients [68].
Could a positive culture with a clear antibiogram have led to a more specific susceptibility-based therapy, potentially yielding a more favourable patient outcome, possibly through a combination of L-AmB with a more pathogen-targeted drug-like caspofungin?
The answer is not straightforward, as caspofungin’s role in this case is already contentious, considering it could be considered a potential risk factor for mucormycosis. The concurrent administration of chemotherapy and non-Mucorales-specific antifungals could facilitate species selection [35], as could have potentially happened during her last hospitalization.
These results are in contrast with studies examining antifungal combinations in HSCT and patients with haematological malignancies, which show no difference in mortality rates between combination and single-drug therapy [69]. The last guidelines (2019) underline the lack of definitive data in support of a combination therapy beyond a marginal recommendation. In this limited-data context, combinations of polyenes and azoles or polyenes plus echinocandins are mentioned [70], especially when referring to patients administered with targeted therapies (like our patient) [71]; however, the role of prophylactic azoles in these patients is still matter of dispute [72].
Lastly, the absence of an autopsy conducted by a pathologist was a limitation. Autopsies must be considered, especially in cases without a definitive diagnosis, providing pathologists with a specific clinical question to answer and the opportunity to obtain more suitable or abundant material for analysis.

4. Conclusions

Managing complex fungal infections in CLL patients can prove exceptionally challenging due to their rarity, the limited sensitivity of serological-microbiological techniques, and the limited specificity of histopathological examination of suspicious lesions. The thoughtful application of molecular biology techniques is crucial in achieving a precise diagnosis. Administering poly-antifungal therapies should always be approached with caution, as it can be difficult to accurately assess the risk-benefit ratio of these drugs in relation to the specific mycetes species involved.

Author Contributions

Case report built upon CARE guidelines and checkpoints for case reporting. CRediT authorship: G.M.: conceptualization, investigation, writing—original draft preparation; M.A., E.C. and V.R.: investigation; A.V. and M.F.: conceptualization, writing—review and editing; L.T. and A.A.: supervision—review and editing. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not available.

Informed Consent Statement

Patient consent was waived due to the fact that both the patient and her closest relatives are dead at the time of writing.

Data Availability Statement

No new data were created or analysed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kipps, T.J.; Stevenson, F.K.; Wu, C.J.; Croce, C.M.; Packham, G.; Wierda, W.G.; O’Brien, S.; Gribben, J.; Rai, K. Chronic lymphocytic leukaemia. Nat. Rev. Dis. Prim. 2017, 3, 16096. [Google Scholar] [CrossRef] [PubMed]
  2. Forconi, F.; Moss, P. Perturbation of the normal immune system in patients with CLL. Blood 2015, 126, 573–581. [Google Scholar] [CrossRef] [PubMed]
  3. Fayad, L.; Keating, M.J.; Reuben, J.M.; O’Brien, S.; Lee, B.-N.; Lerner, S.; Kurzrock, R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: Correlation with phenotypic characteristics and outcome. Blood 2001, 97, 256–263. [Google Scholar] [CrossRef]
  4. Ramsay, A.G.; Johnson, A.J.; Lee, A.M.; Gorgün, G.; Le Dieu, R.; Blum, W.; Byrd, J.C.; Gribben, J.G. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Investig. 2008, 118, 2427–2437. [Google Scholar] [CrossRef] [PubMed]
  5. Herishanu, Y.; Pérez-Galán, P.; Liu, D.; Biancotto, A.; Pittaluga, S.; Vire, B.; Gibellini, F.; Njuguna, N.; Lee, E.; Stennett, L.; et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011, 117, 563–574. [Google Scholar] [CrossRef]
  6. Peters, F.S.; Strefford, J.C.; Eldering, E.; Kater, A. T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective. Haematologica 2021, 106, 1234–1243. [Google Scholar] [CrossRef]
  7. Visentin, A.; Molinari, M.C.; Pravato, S.; Cellini, A.; Angotzi, F.; Cavaretta, C.A.; Ruocco, V.; Imbergamo, S.; Piazza, F.; Proietti, G.; et al. A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency. Curr. Oncol. 2023, 30, 274–283. [Google Scholar] [CrossRef]
  8. Dhalla, F.; Lucas, M.; Schuh, A.; Bhole, M.; Jain, R.; Patel, S.Y.; Misbah, S.; Chapel, H. Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin? J. Clin. Immunol. 2014, 34, 277–282. [Google Scholar] [CrossRef]
  9. Noto, A.; Cassin, R.; Mattiello, V.; Bortolotti, M.; Reda, G.; Barcellini, W. Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia? Front. Immunol. 2023, 14, 1062376. [Google Scholar] [CrossRef]
  10. Mohamed, A.J.; Yu, L.; Bäckesjö, C.-M.; Vargas, L.; Faryal, R.; Aints, A.; Christensson, B.; Berglöf, A.; Vihinen, M.; Nore, B.F.; et al. Bruton’s tyrosine kinase (Btk): Function, regulation, and transformation with special emphasis on the PH domain. Immunol. Rev. 2009, 228, 58–73. [Google Scholar] [CrossRef]
  11. Tasso, B.; Spallarossa, A.; Russo, E.; Brullo, C. The Development of BTK Inhibitors: A Five-Year Update. Molecules 2021, 26, 7411. [Google Scholar] [CrossRef] [PubMed]
  12. Maffei, R.; Maccaferri, M.; Arletti, L.; Fiorcari, S.; Benatti, S.; Potenza, L.; Luppi, M.; Marasca, R. Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections. Blood Rev. 2020, 40, 100635. [Google Scholar] [CrossRef] [PubMed]
  13. Dubovsky, J.A.; Beckwith, K.A.; Natarajan, G.; Woyach, J.A.; Jaglowski, S.; Zhong, Y.; Hessler, J.D.; Liu, T.-M.; Chang, B.Y.; Larkin, K.M.; et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013, 122, 2539–2549. [Google Scholar] [CrossRef] [PubMed]
  14. Strijbis, K.; Tafesse, F.G.; Fairn, G.D.; Witte, M.D.; Dougan, S.K.; Watson, N.; Spooner, E.; Esteban, A.; Vyas, V.K.; Fink, G.R.; et al. Bruton’s Tyrosine Kinase (BTK) and Vav1 Contribute to Dectin1-Dependent Phagocytosis of Candida albicans in Macrophages. PLoS Pathog. 2013, 9, e1003446. [Google Scholar] [CrossRef]
  15. Varughese, T.; Taur, Y.; Cohen, N.; Palomba, M.L.; Seo, S.K.; Hohl, T.M.; Redelman-Sidi, G. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. Clin. Infect. Dis. 2018, 67, 687–692. [Google Scholar] [CrossRef]
  16. Pilmis, B.; Kherabi, Y.; Huriez, P.; Zahar, J.-R.; Mokart, D. Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas. Cancers 2023, 15, 1989. [Google Scholar] [CrossRef]
  17. Estupiñán, H.Y.; Berglöf, A.; Zain, R.; Smith, C.I.E. Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. Front. Cell Dev. Biol. 2021, 9, 630942. [Google Scholar] [CrossRef]
  18. Little, J.S.; Weiss, Z.F.; Hammond, S. Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies. J. Fungi 2021, 7, 1058. [Google Scholar] [CrossRef]
  19. Ruiz-Camps, I.; Aguilar-Company, J. Risk of infection associated with targeted therapies for solid organ and hematological malignancies. Ther. Adv. Infect. Dis. 2021, 8, 204993612198954. [Google Scholar] [CrossRef]
  20. Walther, G.; Wagner, L.; Kurzai, O. Updates on the taxonomy of mucorales with an emphasis on clinically important taxa. J. Fungi 2019, 5, 106. [Google Scholar] [CrossRef]
  21. Kwon-Chung, K.J. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: Molecular mycologic perspectives. Clin. Infect. Dis. 2012, 54 (Suppl. 1), S8–S15. [Google Scholar] [CrossRef]
  22. Spatafora, J.W.; Chang, Y.; Benny, G.L.; Lazarus, K.; Smith, M.E.; Berbee, M.L.; Bonito, G.; Corradi, N.; Grigoriev, I.; Gryganskyi, A.; et al. A phylum-level phylogenetic classification of zygomycete fungi based on genome-scale data. Mycologia 2016, 108, 1028–1046. [Google Scholar] [CrossRef] [PubMed]
  23. Wijayawardene, N.N.; Pawłowska, J.; Letcher, P.M.; Kirk, P.M.; Humber, R.A.; Schüßler, A.; Wrzosek, M.; Muszewska, A.; Okrasińska, A.; Istel, Ł.; et al. Notes for genera: Basal clades of Fungi (including Aphelidiomycota, Basidiobolomycota, Blastocladiomycota, Calcarisporiellomycota, Caulochytriomycota, Chytridiomycota, Entomophthoromycota, Glomeromycota, Kickxellomycota, Monoblepharomycota, Mortierellomyc. Fungal Divers. 2018, 92, 43–129. [Google Scholar] [CrossRef]
  24. Wagner, L.; de Hoog, S.; Alastruey-Izquierdo, A.; Voigt, K.; Kurzai, O.; Walther, G. A revised species concept for opportunistic Mucor species reveals species-specific antifungal susceptibility profiles. Antimicrob. Agents Chemother. 2019, 63, 1–8. [Google Scholar] [CrossRef] [PubMed]
  25. Jeong, W.; Keighley, C.; Wolfe, R.; Lee, W.L.; Slavin, M.A.; Kong, D.C.M.; Chen, S.C.-A. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin. Microbiol. Infect. 2019, 25, 26–34. [Google Scholar] [CrossRef]
  26. Nicolás, F.E.; Murcia, L.; Navarro, E.; Navarro-Mendoza, M.I.; Pérez-Arques, C.; Garre, V. Mucorales species and macrophages. J. Fungi 2020, 6, 94. [Google Scholar] [CrossRef]
  27. Petrikkos, G.; Skiada, A.; Lortholary, O.; Roilides, E.; Walsh, T.J.; Kontoyiannis, D. Epidemiology and Clinical Manifestations of Mucormycosis. Clin. Infect. Dis. 2012, 54 (Suppl. 1), S23–S34. [Google Scholar] [CrossRef]
  28. Hlaing, K.M.; Monday, L.M.; Nucci, M.; Nouér, S.A.; Revankar, S.G. Invasive Fungal Infections Associated with COVID-19. J. Fungi 2023, 9, 667. [Google Scholar] [CrossRef]
  29. Sharma, B.; Nonzom, S. Mucormycosis and Its Upsurge during COVID-19 Epidemic: An Updated Review. Curr. Microbiol. 2023, 80, 322. [Google Scholar] [CrossRef]
  30. Walther, G.; Wagner, L.; Kurzai, O. Outbreaks of Mucorales and the Species Involved. Mycopathologia 2020, 185, 765–781. [Google Scholar] [CrossRef]
  31. Roden, M.M.; Zaoutis, T.E.; Buchanan, W.L.; Knudsen, T.A.; Sarkisova, T.A.; Schaufele, R.L.; Sein, M.; Sein, T.; Chiou, C.C.; Chu, J.H.; et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin. Infect. Dis. 2005, 41, 634–653. [Google Scholar] [CrossRef] [PubMed]
  32. Chayakulkeeree, M.; Ghannoum, M.A.; Perfect, J.R. Zygomycosis: The re-emerging fungal infection. Eur. J. Clin. Microbiol. Infect. Dis. 2006, 25, 215–229. [Google Scholar] [CrossRef] [PubMed]
  33. Chakrabarti, A.; Chatterjee, S.S.; Das, A.; Panda, N.; Shivaprakash, M.R.; Kaur, A.; Varma, S.C.; Singhi, S.; Bhansali, A.; Sakhuja, V. Invasive zygomycosis in India: Experience in a tertiary care hospital. Postgrad. Med. J. 2009, 85, 573–581. [Google Scholar] [CrossRef] [PubMed]
  34. Roilides, E.; Zaoutis, T.E.; Katragkou, A.; Benjamin, D.K.; Walsh, T.J. Zygomycosis in neonates: An uncommon but life-threatening infection. Am. J. Perinatol. 2009, 26, 565–573. [Google Scholar] [CrossRef]
  35. Meis, J.F.; Chakrabarti, A. Changing epidemiology of an emerging infection: Zygomycosis. Clin. Microbiol. Infect. 2009, 15 (Suppl. 5), 10–14. [Google Scholar] [CrossRef]
  36. Lecointe, K.; Cornu, M.; Leroy, J.; Coulon, P.; Sendid, B. Polysaccharides cell wall architecture of mucorales. Front. Microbiol. 2019, 10, 469. [Google Scholar] [CrossRef]
  37. Ellis, M.; Al-Ramadi, B.; Finkelman, M.; Hedstrom, U.; Kristensen, J.; Ali-Zadeh, H.; Klingspor, L. Assessment of the clinical utility of serial β-d-glucan concentrations in patients with persistent neutropenic fever. J. Med. Microbiol. 2008, 57, 287–295. [Google Scholar] [CrossRef]
  38. Odabasi, Z.; Mattiuzzi, G.; Estey, E.; Kantarjian, H.; Saeki, F.; Ridge, R.J.; Ketchum, P.A.; Finkelman, M.A.; Rex, J.H.; Ostrosky-Zeichner, L. -D-Glucan as a Diagnostic Adjunct for Invasive Fungal Infections: Validation, Cutoff Development, and Performance in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Clin. Infect. Dis. 2004, 39, 199–205. [Google Scholar] [CrossRef]
  39. Maertens, J.A.; Klont, R.; Masson, C.; Theunissen, K.; Meersseman, W.; Lagrou, K.; Heinen, C.; Crepin, B.; Eldere, J.V.; Tabouret, M.; et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin. Infect. Dis. 2007, 44, 1329–1336. [Google Scholar] [CrossRef]
  40. Miceli, M.H.; Kauffman, C.A. Aspergillus Galactomannan for Diagnosing Invasive Aspergillosis. JAMA 2017, 318, 1175–1176. [Google Scholar] [CrossRef]
  41. Millon, L.; Herbrecht, R.; Grenouillet, F.; Morio, F.; Alanio, A.; Letscher-Bru, V.; Cassaing, S.; Chouaki, T.; Kauffmann-Lacroix, C.; Poirier, P.; et al. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: Retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). Clin. Microbiol. Infect. 2016, 22, 810.e1–810.e8. [Google Scholar] [CrossRef]
  42. Bitar, D.; Van Cauteren, D.; Lanternier, F.; Dannaoui, E.; Che, D.; Dromer, F.; Desenclos, J.-C.; Lortholary, O. Increasing incidence of zygomycosis (mucormycosis), France 1997–2006. Emerg. Infect. Dis. 2009, 15, 1395–1401. [Google Scholar] [CrossRef]
  43. Alghamdi, A.; Lutynski, A.; Minden, M.; Rotstein, C. Successful Treatment of Gastrointestinal Mucormycosis in an Adult with Acute Leukemia: Case Report and Literature Review. Curr. Oncol. 2017, 24, 61–64. [Google Scholar] [CrossRef]
  44. Prakash, H.; Chakrabarti, A. Global epidemiology of mucormycosis. J. Fungi 2019, 5, 26. [Google Scholar] [CrossRef]
  45. Skiada, A.; Pagano, L.; Groll, A.; Zimmerli, S.; Dupont, B.; Lagrou, K.; Lass-Florl, C.; Bouza, E.; Klimko, N.; Gaustad, P.; et al. Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin. Microbiol. Infect. 2011, 17, 1859–1867. [Google Scholar] [CrossRef]
  46. Tilak, R.; Raina, P.; Gupta, S.; Tilak, V.; Prakash, P.; Gulati, A. Cutaneous zygomycosis: A possible postoperative complication in immunocompetent individuals. Indian J. Dermatol. Venereol. Leprol. 2009, 75, 596–599. [Google Scholar] [CrossRef] [PubMed]
  47. Sridhara, S.R.; Paragache, G.; Panda, N.K.; Chakrabarti, A. Mucormycosis in immunocompetent individuals: An increasing trend. J. Otolaryngol. 2005, 34, 402–406. [Google Scholar] [CrossRef] [PubMed]
  48. Heimann, S.; Vehreschild, M.; Cornely, O.; Heinz, W.; Grüner, B.; Silling, G.; Kessel, J.; Seidel, D.; Vehreschild, J. Healthcare burden of probable and proven invasive mucormycosis: A multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016. J. Hosp. Infect. 2019, 101, 339–346. [Google Scholar] [CrossRef]
  49. Kontoyiannis, D.P.; Yang, H.; Song, J.; Kelkar, S.S.; Yang, X.; Azie, N.; Harrington, R.; Fan, A.; Lee, E.; Spalding, J.R. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: A retrospective study. BMC Infect. Dis. 2016, 16, 730. [Google Scholar] [CrossRef] [PubMed]
  50. Visentin, A.; Facco, M.; Gurrieri, C.; Pagnin, E.; Martini, V.; Imbergamo, S.; Frezzato, F.; Trimarco, V.; Severin, F.; Raggi, F.; et al. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. Clin. Lymphoma Myeloma Leuk. 2019, 19, 678–685.e4. [Google Scholar] [CrossRef]
  51. Visentin, A.; Bonaldi, L.; Rigolin, G.M.; Mauro, F.R.; Martines, A.; Frezzato, F.; Pravato, S.; Gargarella, L.R.; Bardi, M.A.; Cavallari, M.; et al. The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. Haematologica 2021, 107, 868–876. [Google Scholar] [CrossRef]
  52. Chakrabarti, A. Cutaneous zygomycosis: Major concerns. Indian J. Med. Res. 2010, 131, 739–741. [Google Scholar]
  53. Walsh, T.J.; Gamaletsou, M.N.; McGinnis, M.R.; Hayden, R.T.; Kontoyiannis, D. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin. Infect. Dis. 2012, 54 (Suppl. 1), 55–60. [Google Scholar] [CrossRef]
  54. Marchesini, G.; Nadali, G.; Facchinelli, D.; Candoni, A.; Cattaneo, C.; Laurenti, L.; Fanci, R.; Farina, F.; Lessi, F.; Visentin, A.; et al. Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study. Br. J. Haematol. 2021, 193, 316–324. [Google Scholar] [CrossRef]
  55. Tisi, M.C.; Hohaus, S.; Cuccaro, A.; Innocenti, I.; De Carolis, E.; Za, T.; D’alò, F.; Laurenti, L.; Fianchi, L.; Sica, S.; et al. Invasive fungal infections in chronic lymphoproliferative disorders: A monocentric retrospective study. Haematologica 2017, 102, e108–e111. [Google Scholar] [CrossRef] [PubMed]
  56. Visentin, A.; Gurrieri, C.; Imbergamo, S.; Lessi, F.; Di Maggio, S.A.; Frezzato, F.; Adami, F.; Zambello, R.; Piazza, F.; Semenzato, G.; et al. Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. Hematol. Oncol. 2017, 35, 925–928. [Google Scholar] [CrossRef]
  57. Visentin, A.; Mauro, F.R.; Cibien, F.; Vitale, C.; Reda, G.; Fresa, A.; Ciolli, S.; Pietrasanta, D.; Marchetti, M.; Murru, R.; et al. Continuous treatment with Ibrutinib in 100 untreated patients with TP 53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. Am. J. Hematol. 2022, 97, E95–E99. [Google Scholar] [CrossRef] [PubMed]
  58. Mauro, F.R.; Giannarelli, D.; Visentin, A.; Reda, G.; Sportoletti, P.; Frustaci, A.M.; Chiarenza, A.; Ciolli, S.; Vitale, C.; Laurenti, L.; et al. Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Cancers 2021, 13, 3240. [Google Scholar] [CrossRef] [PubMed]
  59. Fiorcari, S.; Maffei, R.; Vallerini, D.; Scarfò, L.; Barozzi, P.; Maccaferri, M.; Potenza, L.; Ghia, P.; Luppi, M.; Marasca, R. BTK Inhibition Impairs the Innate Response against Fungal Infection in Patients with Chronic Lymphocytic Leukemia. Front. Immunol. 2020, 11, 2158. [Google Scholar] [CrossRef]
  60. Krunic, A.L.; Medenica, M.; Busbey, S. Solitary embolic cutaneous aspergillosis in the immunocompromised patient with acute myelogenous leukemia—A propos another case caused by Aspergillus flavus. Int. J. Dermatol. 2003, 42, 946–950. [Google Scholar] [CrossRef]
  61. Skiada, A.; Pavleas, I.; Drogari-Apiranthitou, M. Epidemiology and Diagnosis of Mucormycosis: An Update. J. Fungi 2020, 6, 265. [Google Scholar] [CrossRef] [PubMed]
  62. Burnham-Marusich, A.R.; Hubbard, B.; Kvam, A.J.; Gates-Hollingsworth, M.; Green, H.R.; Soukup, E.; Limper, A.H.; Kozel, T.R. Conservation of Mannan Synthesis in Fungi of the Zygomycota and Ascomycota Reveals a Broad Diagnostic Target. mSphere 2018, 3, e00094-18. [Google Scholar] [CrossRef] [PubMed]
  63. Schwarz, P.; Cornely, O.A.; Dannaoui, E. Antifungal combinations in Mucorales: A microbiological perspective. Mycoses 2019, 62, 746–760. [Google Scholar] [CrossRef] [PubMed]
  64. Dannaoui, E. Antifungal resistance in mucorales. Int. J. Antimicrob. Agents 2017, 50, 617–621. [Google Scholar] [CrossRef] [PubMed]
  65. Spellberg, B.; Fu, Y.; Edwards, J.E.; Ibrahim, A.S. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob. Agents Chemother. 2005, 49, 830–832. [Google Scholar] [CrossRef] [PubMed]
  66. Reed, C.; Bryant, R.; Ibrahim, A.S.; Edwards, J.J.; Filler, S.G.; Goldberg, R.; Spellberg, B. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin. Infect. Dis. 2008, 47, 364–371. [Google Scholar] [CrossRef]
  67. Kazak, E.; Aslan, E.; Akalın, H.; Saraydaroğlu, Ö.; Hakyemez, B.; Erişen, L.; Yazıcı, B.; Gürcüoğlu, E.; Yılmaz, E.; Ener, B.; et al. A mucormycosis case treated with a combination of caspofungin and amphotericin B. J. Mycol. Med. 2013, 23, 179–184. [Google Scholar] [CrossRef] [PubMed]
  68. Gargouri, M.; Marrakchi, C.; Feki, W.; Charfi, S.; Maaloul, I.; Lahiani, D.; Elleuch, E.; Koubaa, M.; Mnif, Z.; Ayadi, A.; et al. Combination of amphotericin B and caspofungin in the treatment of mucormycosis. Med. Mycol. Case Rep. 2019, 26, 32–37. [Google Scholar] [CrossRef]
  69. Kyvernitakis, A.; Torres, H.A.; Jiang, Y.; Chamilos, G.; Lewis, R.E.; Kontoyiannis, D. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: A propensity score analysis. Clin. Microbiol. Infect. 2016, 22, 811.e1–811.e8. [Google Scholar] [CrossRef]
  70. Cornely, O.A.; Alastruey-Izquierdo, A.; Arenz, D.; Chen, S.C.A.; Dannaoui, E.; Hochhegger, B.; Hoenigl, M.; Jensen, H.E.; Lagrou, K.; Lewis, R.E.; et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect. Dis. 2019, 19, e405–e421. [Google Scholar] [CrossRef] [PubMed]
  71. Vallejo, C.; Jarque, I.; Fortun, J.; Casado, A.; Peman, J. IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients. J. Fungi 2023, 9, 628. [Google Scholar] [CrossRef] [PubMed]
  72. Lindsay, J.; Teh, B.W.; Micklethwaite, K.; Slavin, M. Azole antifungals and new targeted therapies for hematological malignancy. Curr. Opin. Infect. Dis. 2019, 32, 538–545. [Google Scholar] [CrossRef] [PubMed]
Curroncol 30 00599 g001
Figure 1. Skin lesions (on the left) showing the tender erythematous lesions and (on the right) necrotizing aspects.
Figure 1. Skin lesions (on the left) showing the tender erythematous lesions and (on the right) necrotizing aspects.
Curroncol 30 00599 g001
Curroncol 30 00599 g002
Figure 2. Slide panoramic showing the angioinvasive fungal mould. Black arrows indicate the hyphae (on the left: HE-10×; on the right: GMS-10×).
Figure 2. Slide panoramic showing the angioinvasive fungal mould. Black arrows indicate the hyphae (on the left: HE-10×; on the right: GMS-10×).
Curroncol 30 00599 g002
Curroncol 30 00599 g003
Figure 3. Details of fungal and vascular structures. Black arrows indicate the hyphae and sporangial bodies (on the left: HE-40×; on the right: GMS-40×).
Figure 3. Details of fungal and vascular structures. Black arrows indicate the hyphae and sporangial bodies (on the left: HE-40×; on the right: GMS-40×).
Curroncol 30 00599 g003
Table 1. Risk factors associated with mucormycosis.
Table 1. Risk factors associated with mucormycosis.
Non-Immunological Risk FactorsImmunological Risk FactorsSpecial and Novel Risk Factors
Decompensated diabetes mellitus and ketoacidosis
[31,32,33]		Immunodepression
Primitive: solid and/or hematologic malignancies; autoimmunity		Premature neonates [34]
Iron overload
Major trauma
Prolonged use of corticosteroids
Intravenous drug abuse [27]
Iatrogenic/secondary: hematopoietic stem cell (HSCT); solid organ transplantPreventive or therapeutic antimycotic drugs (voriconazole, itraconazole, or caspofungin) [35]
BTK inhibitor [12,15,16,17,18,19]
SARS-CoV-2 infecion and treatment [28,29]
Table 2. Synopsis of antitumoral schedule.
Table 2. Synopsis of antitumoral schedule.
2006FCR protocol (Fludarabine-Cyclophosphamide-Rituximab)
2010FCR
2012Rituximab
2013Bendamustine
2014–2016Ibrutinib (discontinued due to infections)
2017–2020Venetoclax
2020Idelalisib-Rituximab
May 2020Zanubrutinib
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Maggioni, G.; Fedrigo, M.; Visentin, A.; Carturan, E.; Ruocco, V.; Trentin, L.; Alaibac, M.; Angelini, A. Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature. Curr. Oncol. 2023, 30, 8255-8265. https://doi.org/10.3390/curroncol30090599

AMA Style

Maggioni G, Fedrigo M, Visentin A, Carturan E, Ruocco V, Trentin L, Alaibac M, Angelini A. Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature. Current Oncology. 2023; 30(9):8255-8265. https://doi.org/10.3390/curroncol30090599

Chicago/Turabian Style

Maggioni, Giuseppe, Marny Fedrigo, Andrea Visentin, Elisa Carturan, Valeria Ruocco, Livio Trentin, Mauro Alaibac, and Annalisa Angelini. 2023. "Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature" Current Oncology 30, no. 9: 8255-8265. https://doi.org/10.3390/curroncol30090599

APA Style

Maggioni, G., Fedrigo, M., Visentin, A., Carturan, E., Ruocco, V., Trentin, L., Alaibac, M., & Angelini, A. (2023). Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature. Current Oncology, 30(9), 8255-8265. https://doi.org/10.3390/curroncol30090599

Article Metrics

Back to TopTop